Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05116579
Other study ID # 2021-FXY-171
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 31, 2021
Est. completion date August 31, 2023

Study information

Verified date November 2021
Source Sun Yat-sen University
Contact Yonghong Li, M.D.
Phone +020-87343656
Email liyongh@sysucc.org.cn
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

To evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment


Description:

This clinical study is an open-label, single-center, observational study to evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment in mCRPC patients. A total of 30 participants with second-line treatment failure will be registered in this study. Whole blood collection will be conducted during the treatment for ctDNA detection, homologous recombination repair (HRR) genes testing, personalized panel customization and whole exome sequencing.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date August 31, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers
Gender Male
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: Patients must meet ALL of the following criteria: 1. Willing and able to provide informed consent. 2. Adult males from 18 to 75 years age. 3. History of histologically or cytologically confirmed adenocarcinoma of the prostate with DDR genes mutation (BRCA1/2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L) detected by high throughput sequencing 4. Documented evidence of metastatic castration resistant prostate cancer (mCRPC) and proposed treatment of PARP inhibitors. 5. Evidence of measurable target lesion in imaging studies. 6. Participants can provide adequate formalin fixed paraffin-embedded (FFPE) tumor tissue collected before any treatment: tumor cell content>30% and necrotic cells<10%. 7. ECOG performance status 0-1 8. Estimated survival=12 weeks Exclusion Criteria: Patients must NOT meet any of the following criteria: 1. Do not meet the inclusion criteria. 2. Under any other anti-tumor therapy like chemotherapy and/or immunotherapy. 3. Receiving organ transplantation in the last 3 months. 4. Participants with autoimmune diseases or history of HBV, HCV or HIV infection (acute or chronic). 5. Participants with pneumonia. 6. Severe concurrent illness or co-morbid disease that would make the subject unsuitable for enrolment 7. Unwilling and unable to provide informed consent. 8. Patients who are judged unsuitable for clinical trial participation by the investigators. Elimination Criteria: Violation of the prescribed rule of medication that may influence the judgment of curative effect and safety.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Radiological progression free survival (rPFS) Radiological progression free survival (rPFS) - defined as the time from randomisation to radiological progression, assessed by investigator per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 (soft tissue) and Prostate Cancer Working Group-3 (PCWG-3) criteria (bone), or death from any cause, or the last follow-up, whichever occurs first From date of randomisation to until radiographic progression (up to 1 year)
Primary Objective Response Rate (ORR) ORR is the percentage of patients with at least one visit response of Complete response (CR) or Partial response (PR), in their soft tissue disease assessed by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), in the absence of progression on bone scan assessed by Prostate Cancer Working Group 3 (PCWG3)). Per RECIST v1.1, CR=Disappearance of all target lesions; PR = >=30% decrease in the sum of diameters of target lesions; For each treatment group, ORR is the number of patients with a CR and PR. From randomisation until radiographic progression (up to 1 year)
Primary PSA response rate PSA response rate is defined as the proportion of patients with a PSA decline (defined as a =30%, =50% and other declines in PSA from baseline). From randomisation until radiographic progression (up to 1 year)
Secondary Overall Survival (OS) OS is defined as time from treatment commencement to death of any cause 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04986423 - ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT05489991 - A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Active, not recruiting NCT05521412 - EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T Phase 1/Phase 2
Terminated NCT04556617 - PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Completed NCT02125357 - Sequencing Abiraterone and Enzalutamide in mCRPC Phase 2
Recruiting NCT06052306 - A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) Phase 1
Recruiting NCT05917470 - A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Phase 1/Phase 2
Recruiting NCT05519449 - Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) Phase 1
Terminated NCT05301062 - A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Recruiting NCT05383079 - Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT04060394 - Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Phase 1/Phase 2
Completed NCT01942837 - Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer Phase 2
Recruiting NCT05458544 - [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application Phase 1/Phase 2
Withdrawn NCT04879589 - Phase 1 Study of ATRS-2002 in Healthy Male Adults Phase 1
Recruiting NCT03230734 - Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer Phase 2
Active, not recruiting NCT03732820 - Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer Phase 3
Recruiting NCT05005728 - XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05762536 - Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC Phase 2
Recruiting NCT06067841 - A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer Phase 1